BioTime to Report First Quarter 2019 Financial Results and Provide Business Update on May 9, 2019
May 03 2019 - 8:00AM
Business Wire
BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage
biotechnology company developing new cellular therapies, today
announced that it will report its first quarter 2019 financial and
operating results on Thursday, May 9th, 2019, following the close
of the U.S. financial markets. BioTime management will also host a
conference call and webcast on Thursday, May 9th, 2019, at 4:30
p.m. Eastern Time/1:30 p.m. Pacific Time to discuss its first
quarter 2019 financial results and to provide a business
update.
Interested parties may access the conference call by dialing
(866) 888-8633 from the U.S. and Canada and (636) 812-6629 from
elsewhere outside the U.S. and should request the “BioTime Inc.
Call”. A live webcast of the conference call will be available
online in the Investors section of BioTime’s website. A replay of
the webcast will be available on BioTime’s website for 30 days and
a telephone replay will be available through May 16th, 2019,
by dialing (855) 859-2056 from the U.S. and Canada and (404)
537-3406 from elsewhere outside the U.S. and entering conference ID
number 9155549.
About BioTime, Inc.
BioTime is a clinical-stage biotechnology company developing new
cellular therapies for degenerative retinal diseases, neurological
conditions associated with demyelination, and aiding the body in
detecting and combating cancer. BioTime’s programs are based on its
proprietary cell-based therapy platform and associated development
and manufacturing capabilities. With this platform BioTime develops
and manufactures specialized, terminally-differentiated human cells
from its pluripotent and progenitor cell starting materials. These
differentiated cells are developed either to replace or support
cells that are dysfunctional or absent due to degenerative disease
or traumatic injury, or administered as a means of helping the body
mount an effective immune response to cancer. BioTime’s clinical
assets include (i) OpRegen®, a retinal pigment epithelium
transplant therapy in Phase I/IIa development for the treatment of
dry age-related macular degeneration, the leading cause of
blindness in the developed world; (ii) OPC1, an oligodendrocyte
progenitor cell therapy in Phase I/IIa development for the
treatment of acute spinal cord injuries; and (iii) VAC2, an
allogeneic cancer immunotherapy of antigen-presenting dendritic
cells currently in Phase I development for the treatment of
non-small cell lung cancer. For more information, please visit
www.biotimeinc.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190503005062/en/
BioTime Inc. IRIoana C. Hone(ir@biotimeinc.com)(510)
871-4188
Solebury Trout IRGitanjali Jain
Ogawa(Gogawa@troutgroup.com)(646) 378-2949
Brooklyn ImmunoTherapeut... (AMEX:BTX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Brooklyn ImmunoTherapeut... (AMEX:BTX)
Historical Stock Chart
From Sep 2023 to Sep 2024